表紙
市場調查報告書

多系統萎縮症(MSA,Shy-Drager症候群,多系統變性症):開發中產品分析

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 410989
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
多系統萎縮症(MSA,Shy-Drager症候群,多系統變性症):開發中產品分析 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H2 2019
出版日期: 2019年12月16日內容資訊: 英文 87 Pages
簡介

所謂多系統萎縮症(MSA) 、或Shy-Drager症候群,是血壓和心率、膀胱功能、消化等,身體的非自主機能損壞的神經退化性疾病。症狀有肌肉的僵直、 行動緩慢、顫動、構音障礙、吞嚥障礙、便秘、失禁、心律不整等。治療使用抗帕金森氏症藥以緩和症狀為目的。

本報告提供多系統萎縮症(MSA,Shy-Drager症候群,多系統變性症)的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等。

簡介

  • 調查範圍

多系統萎縮症(MSA,Shy-Drager症候群,多系統變性症) 概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

開發治療藥的企業

  • AFFiRiS AG
  • AstraZeneca Plc
  • Corestem Inc
  • MitoDys Therapeutics Ltd
  • Modag GmbH
  • Neuropore Therapies Inc
  • Prana Biotechnology Ltd

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Anle-138b
  • AZD-3241
  • CS-10BR05
  • NPT-20011
  • PBT-434
  • PD-01
  • PD-03
  • 神經退化性疾病用小分子

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11613IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy - Pipeline Review, H2 2019, provides an overview of the Multiple System Atrophy (Central Nervous System) pipeline landscape.

Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple System Atrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Multiple System Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple System Atrophy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Multiple System Atrophy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple System Atrophy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple System Atrophy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple System Atrophy (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple System Atrophy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple System Atrophy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Overview
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Companies Involved in Therapeutics Development
    • 1st Bio Therapeutics Inc
    • Alterity Therapeutics Ltd
    • Arvinas Inc
    • Biogen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
    • Corestem Inc
    • Denali Therapeutics Inc
    • EmeraMed Ltd
    • ICB International Inc
    • Inhibikase Therapeutics Inc
    • MitoDys Therapeutics Ltd
    • Modag GmbH
    • Neuropore Therapies Inc
    • Newron Pharmaceuticals SpA
    • ProMIS Neurosciences Inc
    • Stealth BioTherapeutics Corp
    • United Neuroscience Ltd
    • Voyager Therapeutics Inc
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drug Profiles
    • 1ST-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Anle-138b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIIB-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-10BR05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emeramide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapies to Inhibit SNCA for Neurology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IkT-148X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Alpha Synuclein for Multiple System Atrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MSA-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-20011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBT-434 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • safinamide mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBT-272 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Alpha Synuclein for Multiple System Atrophy and Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Neurodegenerative Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UB-312 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • verdiperstat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Dormant Projects
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 18, 2019: Alterity's lead drug candidate receives positive opinion from European medical agency
      • Oct 17, 2019: Arvinas to Present update on Small Molecule to Inhibit Alpha Synuclein for Multiple System Atrophy and Parkinson's Disease at the 2nd Targeted Protein Degradation Summit
      • Sep 25, 2019: Alterity presents clinical data on PBT434 at the 2019 MDS Congress
      • Aug 01, 2019: Biohaven initiates enrolment in verdiperstat's study for MSA
      • Jul 29, 2019: Alterity Therapeutics announces successful completion of phase 1 clinical trial
      • May 07, 2019: Biohaven provides update on verdiperstat from its MPO platform
      • May 06, 2019: Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting
      • May 03, 2019: Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting
      • Apr 10, 2019: Alterity Therapeutics launches to Asian investors
      • Feb 19, 2019: Biohaven's Verdiperstat receives Orphan Drug Designation From FDA For multiple system atrophy
      • Jan 31, 2019: Prana receives Orphan Designation for PBT434 for treatment of MSA
      • Jan 23, 2019: Biohaven receives FDA may proceed letter for phase 3 clinical trial of BHV-3241 for multiple system atrophy
      • Mar 06, 2018: PBT434 poster presented at the 6th International Multiple System Atrophy Conference
      • Dec 04, 2017: ICBII Announces the Filing of Orphan Drug Designation Application for the Use of alpha-Synuclein-SMART Molecule in the Treatment of Multiple System Atrophy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by 1st Bio Therapeutics Inc, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Alterity Therapeutics Ltd, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Arvinas Inc, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Biogen Inc, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Corestem Inc, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Denali Therapeutics Inc, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by EmeraMed Ltd, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by ICB International Inc, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Inhibikase Therapeutics Inc, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by MitoDys Therapeutics Ltd, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Modag GmbH, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Neuropore Therapies Inc, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Newron Pharmaceuticals SpA, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by ProMIS Neurosciences Inc, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Stealth BioTherapeutics Corp, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by United Neuroscience Ltd, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Voyager Therapeutics Inc, H2 2019
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top